The National Institute for Health and Care Excellence (NICE) has recommended Blueprint Medicines’ Ayvakyt (avapritinib) to ...

The US Food and Drug Administration (FDA) has approved Journey Medical’s Emrosi (minocycline hydrochloride extended release capsules 40mg) to treat inflammatory lesions of rosacea in adults. Affecting ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the European Commission (EC) to treat eosinophilic ...

Get ready for an exciting experience at AASLD 2024! The Medscape team is thrilled to be in San Diego from November 15-19 for ...

The companies will use Ascendis’ TransCon technology to develop therapies for metabolic and cardiovascular diseases ...

Medscape Education is committed to disseminating the outcomes of the education programs through peer-reviewed publications ...

Johnson & Johnson (J&J) has announced that its pan-FGFR tyrosine kinase inhibitor Balversa (erdafitinib) has been granted ...

Around 86% of clinical trials do not meet patient recruitment goals, ultimately failing to improve patient outcomes and ...

EatMoreFruit, a UK top 10 independent healthcare communication agency, today announced the launch of its European Network to ...

Dermavant Sciences has shared positive long-term results for its plaque psoriasis-approved Vtama (tapinarof) cream in adults and children as young as two years old with atopic dermatitis (AD).

Launches have the power to significantly shape an organisation’s trajectory, and ensuring their success is critical for long-term growth. Knowing this, it amazes me how many pharmaceutical ...

Novo Nordisk has shared promising results from a late-stage study of semaglutide in patients with metabolic dysfunction-associated steatohepatitis (MASH), a progressive metabolic disease that affects ...